Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market
Key Highlights
- ➤Moderna-Merck intismeran plus KEYTRUDA cut melanoma recurrence or death risk 42%
- ➤Iovance lifileucel plus pembrolizumab delivered 62.5% ORR in frontline advanced melanoma
- ➤Genmab petosemtamab combination achieved 75% first-line colorectal cancer ORR
- ➤Pfizer 25vPnC vaccine generated immune responses against all 25 infant serotypes
- ➤GT Biopharma selected for oral presentation at SITC 2026
Expert Statements
Ruth Vera, Medical Oncology Department, Hospital Universitario de Navarra, and study investigator
“Despite advances in the treatment of metastatic colorectal cancer, outcomes remain poor for many patients once disease has spread, including those with RAS/BRAF wild-type disease who may face limited options after standard chemotherapy and targeted therapy”
Ruth Vera, Medical Oncology Department, Hospital Universitario de Navarra, and study investigator
“The encouraging response rates observed in both the first- and second-line settings, along with the maturation of the dataset over time, suggest that treatment with petosemtamab plus chemotherapy may offer a potential new approach for these patients.”
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Cancer treatment is moving into a new phase, and immuno-oncology is right at the center of it. Instead of relying only on drugs that attack tumors directly, researchers are developing treatments that help the body's own immune system recognize and fight cancer. Some of the biggest areas to watch include personalized cancer vaccines, CAR-T cell therapies, bispecific antibodies and new drugs designed to help patients who280 no longer respond to existing treatments. The science is advancing, and drugmakers are working to turn promising research into treatments that can make a real difference for patients. For biotech companies, a successful clinical trial or a major drug approval can be a game changer. Discover the biotech companies driving the next wave of growth and opportunity: GT Biopharma, Inc. (NASDAQ: GTBP), Moderna, Inc. (NASDAQ: MRNA), Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), Genmab A/S (NASDAQ: GMAB), Pfizer Inc. (NYSE: PFE).
Get started
Create a free account to read the full story.